Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Remedy Applications Inc., known as Remedy, is a healthcare technology company based in Austin, Texas, founded in 2015. The company specializes in on-demand urgent and primary care services, offering innovative delivery methods for healthcare. Remedy provides 24/7 telemedicine, nurse access, lab visits, and house calls, allowing individual patients and large employer clients to receive quality medical care at home. Its software facilitates the booking of healthcare professionals, including nurses and doctors, who are registered with the company, to conduct regular checkups and provide necessary treatment. Through its services, Remedy aims to make healthcare more accessible and affordable for patients.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.
It was founded in 2010 and is headquartered in Houston, Texas.
Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
Ketra, a subsidiary of Lutron Electronics Co., Inc., specializes in manufacturing high-performance LED lighting and integrated control systems for both residential and commercial applications. Founded in 2009 and headquartered in Austin, Texas, the company offers a comprehensive range of products, including various luminaires, lamps, and control systems, such as keypads and mobile applications. Ketra is recognized for its innovative approach to lighting, providing products that enhance natural light environments and improve user well-being. Its full-stack lighting solutions feature advanced technologies that ensure color stability and uniform intensity, promoting better sleep, productivity, and overall health. By delivering a cohesive system of lighting fixtures, controls, and software, Ketra simplifies installation and offers a versatile lighting solution that meets diverse needs.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Healthcare Highways, Inc. is an accountable care organization and health plan based in Frisco, Texas, founded in 2010 by Michael Wilson. The company collaborates with hospitals, providers, employers, payers, and brokers to offer customized healthcare solutions that aim to reduce costs while maintaining high-quality care. Its services include third-party administration, stop-loss coverage, disease management, pharmacy benefit management, and population health initiatives. With a focus on proactive strategies, Healthcare Highways addresses current and emerging challenges in the healthcare landscape by creating innovative plans tailored to the needs of self-insured clients. The company emphasizes the importance of facilitating a smooth transition for consumers and employers in a complex healthcare environment, ultimately striving to deliver sustainable value and improved healthcare outcomes for all stakeholders involved.
Healthcare Highways, Inc. is an accountable care organization and health plan based in Frisco, Texas, founded in 2010 by Michael Wilson. The company collaborates with hospitals, providers, employers, payers, and brokers to offer customized healthcare solutions that aim to reduce costs while maintaining high-quality care. Its services include third-party administration, stop-loss coverage, disease management, pharmacy benefit management, and population health initiatives. With a focus on proactive strategies, Healthcare Highways addresses current and emerging challenges in the healthcare landscape by creating innovative plans tailored to the needs of self-insured clients. The company emphasizes the importance of facilitating a smooth transition for consumers and employers in a complex healthcare environment, ultimately striving to deliver sustainable value and improved healthcare outcomes for all stakeholders involved.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.
LumaTherm
Series A in 2012
LumaTherm, Inc.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.
TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
BioStable is a cardiovascular device company that develops innovative new products for the treatment of cardiovascular diseases. The company is led by an experienced group of industry executives with expertise in rapid and effective medical device development. The organization incorporates core strengths in all areas of product development including quality systems, design, engineering, prototyping and pilot production, in-vitro and in-vivo testing, manufacturing, global regulatory relationships, clinical product validation, market launch, and distribution.
BioStable provides a competitive edge by minimizing time to market for cost-effective medical devices that deliver improved clinical outcomes. The company focused on developing and commercializing proprietary valve repair technologies that provide an alternative to valve replacement for patients with aortic valve disease.
BioStable was founded in
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.
Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢
Spinal Restoration, Inc. focuses on developing innovative therapies for chronic low back pain, emphasizing early intervention and minimally invasive techniques. The company's primary product is the Biostat System, which includes a proprietary resorbable biologic compound and a specialized delivery system designed to treat discogenic low back pain caused by internal disc disruptions. This system features the BIOSTAT BIOLOGX Fibrin Sealant, a resorbable tissue sealant, and the Biostat Delivery Device, which facilitates the targeted application of the biologic to the intervertebral disc. Founded in 2004 and headquartered in New York, Spinal Restoration aims to address the needs of a significant population, with an estimated four million adults affected by chronic low back pain each year.